Author: admin
Credit: chaikom/Getty Images Boston University researchers say that a measure derived from electroencephalography (EEG) combined with transcranial magnetic stimulation (TMS) can distinguish people with Alzheimer’s disease (AD) from healthy older adults by detecting reduced brain response complexity. The study, published in the journal Neuroscience of Consciousness, that a measure that has been used to assess coma and minimally conscious states, called perturbation complexity index–state transitions (PCI-ST), is lower in individuals with AD, suggesting altered cortical network function related to impaired conscious cognitive processes. If further validated, the use of TMS-EEG to measured PCI-ST could become a quantitative biomarker that could…
Enhanced image showing where genes are active in colon tissue, revealing neutrophils located close to pre-cancerous epithelial cells [Longman Lab] It is known that inflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC). But the underlying mechanism—and the genetic drivers—between this link remain yet to be determined. Genetic variants in TNFSF15, encoding tumor necrosis factor (TNF)-like cytokine 1A (TL1A), are associated with both severe IBD and advanced CRC. Now, a new study points to immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone marrow—to help explain why…
OpenAI, Google, Anthropic and Amazon put health and healthcare front and center in latest AI product launches. Ever since we reported on OpenAI’s recent move into consumer health, it feels like the floodgates have opened when it comes to the big tech firms unveiling significant health-focused AI initiatives. Announcements from Google, Anthropic, and most recently Amazon, demonstrate the huge potential that the world’s leading technology companies see in using AI to advance human health – albeit in quite different ways. OpenAI, which revealed its technology was already being used by millions of people for health-related questions, took a step toward…
Credit: SEBASTIAN KAULITZKI / Getty Images / Science Photo Library The human gut is one of the body’s fastest-renewing organs, constantly replacing its lining to support digestion, nutrient absorption, and recovery from injury. This remarkable turnover depends on intestinal stem cells (ISCs). But as we age, these stem cells lose their regenerative power, contributing to digestive problems, inflammation, and a reduced ability to heal. A new peer-reviewed study published in Stem Cell Reports reveals that this decline may not be inevitable. Instead, researchers show that age-related changes in the gut microbiota—the trillions of microbes living in the intestine—directly impair stem cell function,…
In a new study published in Cell Reports titled, “Altered hepatic metabolism in Down syndrome,” researchers at the University of Colorado Anschutz Linda Crnic Institute for Down Syndrome (Crnic Institute) have uncovered evidence that individuals with Down syndrome experience significant alterations in liver metabolism, including elevated levels of bile acids in the bloodstream and other biomarkers of liver dysfunction. Results suggest that these changes may be modifiable through diet, providing hope for improved health outcomes. The liver removes toxins from blood, produces bile for fat digestion, metabolizes nutrients, and makes proteins for blood clotting, making it an essential organ for detoxification, metabolism and immunity. Using multi-omic analysis…
T cells edited to attack tumor-associated macrophages and produce inflammatory cytokines decrease tumor burden in mice, employing a “Trojan horse” strategy of disarming the tumor’s protectors and opening them up to killing.[SD1] Image credit:©iStock.com, MR1805Chimeric antigen receptor (CAR) T cell therapy improves the detection and elimination of cancerous cells by genetically editing a patient’s immune cells to target tumor-associated antigens. This type of immunotherapy works against multiple types of blood cancers. However, it has been less effective against solid tumors.One of the challenges with targeting tumors in a solid tissue is that the tumor microenvironment (TEM) shields the cancerous cells against…
Jenny Rooke, PhD, started the investment company Genoa Ventures out of frustration. As a geneticist, she saw firsthand how the tools powering life sciences and healthcare lag far behind the complexity of real biology. After stints in industry and investing, Rooke launched the venture capital firm eight years ago to back deeply technical founders building the infrastructure for better biology—tools and platforms that rarely get funded in a world obsessed with therapeutics. Genoa’s core belief is that precision medicine is rooted in informed medicine: integrating molecular, physiological, and multimodal data to guide diagnosis, treatment choice, dosing, and monitoring over time.…
HPA (China) News – October 2025 A leading gut microbiome brand under Novo Nordisk Denmark, Microbiome Labs, has officially established a strategic partnership with Zhongjian Lianxing, a high-end nutrition and health supply chain enterprise in China…. October 27, 2025 See more
Hundred Health founder on why building the ‘decision layer’ is the key to ensuring consumer health data delivers on its potential. The booming biomarker-driven consumer health market was further bolstered by last month’s launch of Hundred Health and its $499-a-year offering that aims to turn endless streams of health data into something more actionable. The company’s personalized 100-day protocols combine twice-yearly blood tests with medical records and wearable data to provide users with clear guidance on proactive ways to improve their health trajectory. Hundred claims its approach can help users drive achievable health improvements compounded over time via highly personalized…
Cellular Origins reports that the company completed the first phase of its collaboration with Fresenius Kabi designed to help scale the manufacturing of cell and gene therapies using advanced robotics and cell processing technologies. This milestone marks the completion of the digital and physical integration of Fresenius Kabi’s CueR Cell Processing System into Cellular Origins’ ConstellationR CGT robotic manufacturing platform. Together, note officials at Cellular Origins, the companies have developed a new and integrated approach to robotic-operated cell processing, following the signing of the original agreement on October 16, 2024. The integration of the Cue and Constellation systems is…